Business
Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2025
MIAMI, August 11, 2025--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on operational progress for the second quarter ended June 30, 2025.
About this update from Akeso, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":292,"url":"https://media.zenfs.com/en/business-wire.com/78fc4f193405555e52612e8e92cb3417"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/XP8dMh12yydIoosOElP9KA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU4NDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/78fc4f193405555e52612e8e92cb3417","width":480,"height":292}},"lazy":false},{"type":"text","content":"Ivonescimab in Combination with Chemotherapy Showed Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in Global Phase III HARMONi Trial Evaluating Patients with EGFRm NSCLC after EGFR TKI Therapy; Positive Trend Observed in Overall Survival","length":283,"tagName":"p","attribs":{}},{"type":"text","content":"Interim Overall Survival Analysis Requested from Chinese Health Authorities Shows a Positive Trend Favoring Ivonescimab Compared to Pembrolizumab in PD-L1 Positive Advanced NSCLC from HARMONi-2 Study Conducted by Akeso in China; Ivonescimab Monotherapy Approved by NMPA in China for 1L PD-L1 Positive Advanced NSCLC","length":315,"tagName":"p","attribs":{}},{"type":"text","content":"Ivonescimab in Combination with Chemotherapy Achieves Statistically Significant, Clinically Meaningful Superiority in PFS vs. Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in HARMONi-6 Study Conducted by Akeso in China","length":268,"tagName":"p","attribs":{}},{"type":"text","content":"Enrollment Continues in Summit's Global Phase III Trials HARMONi-3 in 1L NSCLC and HARMONi-7 in 1L PD-L1 High NSCLC","length":119,"tagName":"p","attribs":{}},{"type":"text","content":"Summit and Revolution Medicines Enter Clinical Collaboration Evaluating Ivonescimab in Combination with Three RAS(ON) Inhibitors in RAS Mutant Tumors","length":149,"tagName":"p","attribs":{}},{"type":"text","content":"MIAMI, August 11, 2025--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on operational progress for the second quarter ended June 30, 2025.","length":272,"tagName":"p"},{"type":"text","content":"Operational & Corporate Updates","length":35,"tagName...